In this study, we evaluated the immunogenicity and protective efficacy of an experimental COVID-19 vaccine comprising the SARS-CoV-2 Spike trimer adjuvanted with the TLR2 agonist, LP1569, and the STING agonist, C-di-GMP, named Spike-LP-GMP. The gene discussed is STING1; the disease is COVID-19.